These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6840181)

  • 1. The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen.
    Woodhouse KW; Hamilton P; Lennard A; Rawlins MD
    Eur J Clin Pharmacol; 1983; 24(2):283-5. PubMed ID: 6840181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma.
    Bosanquet AG; Gilby ED
    Eur J Cancer Clin Oncol; 1982 Apr; 18(4):355-62. PubMed ID: 6889512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral melphalan kinetics.
    Alberts DS; Chang SY; Chen HS; Evans TL; Moon TE
    Clin Pharmacol Ther; 1979 Dec; 26(6):737-45. PubMed ID: 498715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacokinetics of melphalan during intermittent therapy of multiple myeloma.
    Loos U; Musch E; Engel M; Hartlapp JH; Hügl E; Dengler HJ
    Eur J Clin Pharmacol; 1988; 35(2):187-93. PubMed ID: 3191937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma.
    Bosanquet AG; Gilby ED
    Cancer Chemother Pharmacol; 1984; 12(3):183-6. PubMed ID: 6705135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of food on oral melphalan absorption.
    Reece PA; Kotasek D; Morris RG; Dale BM; Sage RE
    Cancer Chemother Pharmacol; 1986; 16(2):194-7. PubMed ID: 3948305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma.
    Taha IA; Ahmad RA; Gray H; Roberts CI; Rogers HJ
    Cancer Chemother Pharmacol; 1982; 9(1):57-60. PubMed ID: 7139852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function in the elimination of oral melphalan in patients with multiple myeloma.
    Adair CG; Bridges JM; Desai ZR
    Cancer Chemother Pharmacol; 1986; 17(2):185-8. PubMed ID: 3719900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interaction of cimetidine with oral melphalan. A pharmacokinetic study.
    Sviland L; Robinson A; Proctor SJ; Bateman DN
    Cancer Chemother Pharmacol; 1987; 20(2):173-5. PubMed ID: 3311444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose intravenous melphalan in advanced multiple myeloma.
    Bäck H; Lindblad R; Rödjer S; Westin J
    Acta Haematol; 1990; 83(4):183-6. PubMed ID: 2115714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Kinetics of intravenous melphalan.
    Alberts DS; Chang SY; Chen HS; Moon TE; Evans TL; Furner RL; Himmelstein K; Gross JF
    Clin Pharmacol Ther; 1979 Jul; 26(1):73-80. PubMed ID: 445964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
    Nath CE; Shaw PJ; Trotman J; Zeng L; Duffull SB; Hegarty G; McLachlan AJ; Gurney H; Kerridge I; Kwan YL; Presgrave P; Tiley C; Joshua D; Earl J
    Br J Clin Pharmacol; 2010 May; 69(5):484-97. PubMed ID: 20573084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma cell myeloma: response of melphalan-resistant patients to high-dose intermittent cyclophosphamide.
    Bergsagel DE; Cowan DH; Hasselback R
    Can Med Assoc J; 1972 Nov; 107(9):851-5. PubMed ID: 4653931
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral melphalan pharmacokinetics: influence of interferon-induced fever.
    Ehrsson H; Eksborg S; Wallin I; Osterborg A; Mellstedt H
    Clin Pharmacol Ther; 1990 Jan; 47(1):86-90. PubMed ID: 2295223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
    Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
    Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR
    Cancer Treat Rep; 1979 Mar; 63(3):399-403. PubMed ID: 427822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Assessment of a nitrosurea combined with cyclophosphamide and prednisone versus melphalan and prednisone in the treatment of multiple myeloma (author's transl)].
    Bezares R; Bomchil G; Saslavsky J; Pavlovsky S; Curutchet M; Quiroga Micheo E; Macchi A; Musso A; Suárez A; Pizzolato M
    Sangre (Barc); 1979; 24(3):241-51. PubMed ID: 472966
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetics of high dose melphalan.
    Hersh MR; Ludden TM; Kuhn JG; Knight WA
    Invest New Drugs; 1983; 1(4):331-4. PubMed ID: 6678879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaco-kinetics of melphalan following oral or intravenous administration in patients with malignant disease.
    Tattersall MH; Jarman M; Newlands ES; Holyhead L; Milstead RA; Weinberg A
    Eur J Cancer (1965); 1978 May; 14(5):507-13. PubMed ID: 648565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.